Tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-4 (IL-4) antibodies and other drugs have been proven useful in treating rheumatoid arthritis (RA), psoriasis, cytokine release syndrome (CRS), atopic dermatitis (AD) and other autoimmune diseases (15–18). This evidence concerns the gene IL6 and congenital rubella syndrome.